Grundläggande statistik
| CIK | 1102942 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InnovaQor, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 16, 2024 |
SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 16, 2024 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Numbe |
|
| April 1, 2024 |
SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2024 |
Exhibit 99.1 INNOVAQOR, INC. ANNOUNCES A REDUCTION OF OUTSTANDING COMMMON SHARES AS A RESULT OF CERTAIN SHAREHOLDERS PARTICIPATING IN A SHARE EXCHANGE WEST PALM BEACH, Fla. (February 21, 2024) — InnovaQor, Inc. (OTC: INQR) announces that, to date, certain common shareholders have agreed to exchange a total of 40,700,000 common shares for shares of Series E and F Preferred Stock at an exchange valu |
|
| February 23, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 19, 2024 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Nu |
|
| December 21, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Nu |
|
| December 21, 2023 |
INNOVAQOR, INC. CEO PROVIDES YEAR END MESSAGE TO SHAREHOLDERS Exhibit 99.1 INNOVAQOR, INC. CEO PROVIDES YEAR END MESSAGE TO SHAREHOLDERS WEST PALM BEACH, Fla. (December 20, 2023) — InnovaQor, Inc. (OTC: INQR) Chief Executive Officer, Darrell Peterson provides the following year end message to shareholders. Dear Fellow Shareholders As we approach the end of 2023 I want to share my optimism about what has been accomplished in 2023 and the strategy and path we |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 4, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Num |
|
| December 8, 2023 |
INNOVAQOR, INC. PROVIDES UPDATE ON CURALLO PRODUCT AND CONTEMPLATED SHARE EXCHANGE Exhibit 99.1 INNOVAQOR, INC. PROVIDES UPDATE ON CURALLO PRODUCT AND CONTEMPLATED SHARE EXCHANGE WEST PALM BEACH, Fla. (December 4, 2023) — InnovaQor, Inc. (OTC: INQR) Chief Executive Officer, Darrell Peterson recently joined Stock Day host Matthew Dunehoo to provide an update on the development of Curallo and discuss the preferred share exchange offer contemplated by the Company. Dunehoo began the |
|
| December 8, 2023 |
InnovaQor, Inc. (INQR) Interview CEO Darrell Peterson – Uptick News- December 2023 Exhibit 99.2 InnovaQor, Inc. (INQR) Interview CEO Darrell Peterson – Uptick News- December 2023 Speakers: Matthew Dunehoo and Darrell Peterson Dunehoo: On today’s show, we’re talking to a company that has been on the show before. The company is InnovaQor, Inc. and they trade on the OTC Market under the trading symbol ‘INQR’. We would like to welcome back the CEO of the company, Darrell Peterson. W |
|
| November 29, 2023 |
CERTIFICATE OF DESIGNATION INNOVAQOR, INC. Exhibit 3.1 EXHIBIT “A” TO CERTIFICATE OF DESIGNATION INNOVAQOR, INC. Section 1. Definitions. For the purposes hereof, the following terms shall have the following meanings: “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Nu |
|
| November 29, 2023 |
CERTIFICATE OF DESIGNATION INNOVAQOR, INC. Exhibit 3.2 EXHIBIT “A” TO CERTIFICATE OF DESIGNATION INNOVAQOR, INC. Section 1. Definitions. For the purposes hereof, the following terms shall have the following meanings: “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the |
|
| November 27, 2023 |
INNOVAQOR, INC. CREATES PREFERRED STOCK; CONSIDERS LAUNCHING EXCHANGE OFFER TO COMMON SHAREHOLDERS Exhibit 99.1 INNOVAQOR, INC. CREATES PREFERRED STOCK; CONSIDERS LAUNCHING EXCHANGE OFFER TO COMMON SHAREHOLDERS WEST PALM BEACH, Fla. (November 27, 2023) — InnovaQor, Inc. (OTC: INQR) authorized two new series of preferred stock, the Series E Mandatory Convertible Preferred Stock and the Series F Mandatory Convertible Preferred Stock, by filing certificates of designation with the Secretary of Sta |
|
| November 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 27, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Nu |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-33191 INN |
|
| November 20, 2023 |
Promissory Note of InnovaQor, Inc., dated December 31, 2022, payable to Rennova Health, Inc.* Exhibit 10.2 PROMISSORY NOTE $1,457,253.00 December 31st 2022 FOR VALUE RECEIVED the undersigned, InnovaQor, Inc. (the “Borrower”), hereby promises to pay to the order of Rennova Health, Inc. (the “Holder or Rennova”), the principal amount of One Million Four Hundred and Fifty Seven Thousand, Two Hundred and Fifty Three dollars on June 30th, 2023 (Maturity date). Whereas. InnovaQor, Inc. is a full |
|
| November 20, 2023 |
Promissory Note of InnovaQor, Inc., dated July 1, 2022, payable to Rennova Health, Inc.* Exhibit 10.1 PROMISSORY NOTE $883,757.27 July 1st, 2022 FOR VALUE RECEIVED the undersigned, InnovaQor, Inc. (the “Borrower”), hereby promises to pay to the order of Rennova Health, Inc. (the “Holder”), the principal amount of Eight hundred and eighty three thousand, seven hundred and fifty seven dollars and twenty seven cents ($883,757.27) on December 31st, 2022 (Maturity date) SUMMARY, InnovaQor, |
|
| November 14, 2023 |
SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 15, 2023 |
InnovaQor, Inc. (INQR) Interview CEO Darrell Peterson – Uptick News – September 2023 Exhibit 99.2 InnovaQor, Inc. (INQR) Interview CEO Darrell Peterson – Uptick News – September 2023 Speakers: Matthew Dunehoo and Darrell Peterson Dunehoo: On today’s show we are talking to a Company that has been on before, but today we are speaking to a new CEO for the first time since he assumed the role back in May. The Company is InnovaQor, Inc., that trades on the OTC market under the trading |
|
| September 15, 2023 |
INNOVAQOR, INC. PROVIDES UPDATE AND CONFIRMS DEVELOPMENT OF NEW PRODUCT Exhibit 99.1 INNOVAQOR, INC. PROVIDES UPDATE AND CONFIRMS DEVELOPMENT OF NEW PRODUCT WEST PALM BEACH, Fla. (September 11, 2023) — InnovaQor, Inc. (OTC: INQR) Chief Executive Officer, Darrell Peterson recently joined Stock Day host Matthew Dunehoo to provide an update and confirm the development of a new product, Curallo. Dunehoo began the interview by asking Peterson to remind his listeners about |
|
| September 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 11, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File N |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-33191 INNOVAQO |
|
| August 14, 2023 |
SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2023 |
___________ The date of this prospectus is August 2, 2023 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-273288 81,651,000 Shares of Common Stock Offered by the Selling Stockholder This prospectus relates to the resale, from time to time, by the selling stockholder listed in this prospectus under the section “Selling Stockholder,” of up to 81,651,000 shares of common stock, par value $.0001 per share, of InnovaQor, Inc., issuable upon the conversi |
|
| July 31, 2023 |
INNOVAQOR, INC. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 (561) 421-1905 INNOVAQOR, INC. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 (561) 421-1905 July 31, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InnovaQor, Inc. Registration Statement on Form S-1 File No. 333-273288 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, In |
|
| July 27, 2023 |
As filed with the Securities and Exchange Commission on July 27, 2023. As filed with the Securities and Exchange Commission on July 27, 2023. Registration No. 333-273288 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 7373 88-0436055 (State or other jurisdiction of incorporation or or |
|
| July 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InnovaQor, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calcula-tion or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Ca |
|
| July 17, 2023 |
As filed with the Securities and Exchange Commission on July 17, 2023. As filed with the Securities and Exchange Commission on July 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 7373 88-0436055 (State or other jurisdiction of incorporation or organization) (Primary Stan |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 29, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Number |
|
| July 6, 2023 |
Exhibit 3.1 Exhibit “A” to Certificate of Amendment ARTICLE III (A) The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is Two Billion Twenty-Five Million (2,025,000,000) shares, comprised of Two Billion (2,000,000,000) shares of Common Stock, with a par value of $0.0001 per share (the “Common Stock”), and Twenty-Five Million (25,000,000) |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-33191 INNOVAQ |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Numbe |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2023 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Number) |
|
| May 18, 2023 |
Exhibit 10.1 Form of SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2023, between InnovaQor, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| May 18, 2023 |
Exhibit 3.1 EXHIBIT “A” TO CERTIFICATE OF DESIGNATION INNOVAQOR, INC. 1. Designation; Number of Shares. The shares of such series shall be designated as the Series D Non-Convertible Preferred Stock (the “Series D Preferred Stock”). The number of shares of Series D Preferred Stock shall be five hundred (500). Each share of Series D Preferred Stock shall have a par value of $0.0001 per share and a s |
|
| May 12, 2023 |
SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-33191 INNOVAQOR, INC. (Exact name |
|
| April 17, 2023 |
Exhibit 4.1 Description of InnovaQor, Inc.’s Securities The following is a summary of the terms of the common stock, par value $0.0001 per share (the “Common Stock”), of InnovaQor, Inc. (the “Company”), which is the only security of the Company that is registered under the Securities Exchange Act of 1934, as amended. Common Stock The following summary of the terms of the Company’s Common Stock is |
|
| March 31, 2023 |
SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 28, 2022 |
InnovaQor Provides a Summary of its Business and Plans Exhibit 99.1 InnovaQor Provides a Summary of its Business and Plans WEST PALM BEACH, Fla. (November 28, 2022) — InnovaQor, Inc. (OTC: VMCS), Chief Executive Officer Sharon Hollis recently joined Stock Day host Everett Jolly to provide a summary of the business activities of InnovaQor. Jolly began the interview by asking Hollis to explain what InnovaQor did. Hollis explained that InnovaQor is a sof |
|
| November 28, 2022 |
Exhibit 99.2 InnovaQor, Inc. Interview CEO Sharon Hollis on Uptick Newswire November 2022 Speakers: Everett Jolly and Sharon Hollis Jolly: On today?s show I?m bringing you a brand new company, it came on our radar about 30 days ago. The name of the company is InnovaQor, Inc. They trade on the OTC Pink Sheets under the ticker symbol ?VMCS?. With us today is the CEO, she is going to bring us up to s |
|
| November 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 28, 2022 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Nu |
|
| November 23, 2022 |
DEF 14C 1 formdef14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement INNOVAQOR, |
|
| November 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 16, 2022 InnovaQor, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-33191 84-0436055 (Commission File Nu |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-33191 INN |
|
| November 14, 2022 |
InnovaQor, Inc. 75,000,000 Shares of Common Stock Filed Pursuant to Rule 253(g)(1) File No. 024-12042 OFFERING CIRCULAR InnovaQor, Inc. 75,000,000 Shares of Common Stock By this Offering Circular, InnovaQor, Inc., a Nevada corporation known as VisualMED Clinical Solutions Corp. in the public trading markets, is offering for sale a maximum of 75,000,000 shares of its common stock (the “Offered Shares”), at a fixed price of $0.005 per share, pursua |
|
| November 14, 2022 |
NT 10-Q 1 formnt10-q.htm SEC FILE NUMBER 000-33191 CUSIP NUMBER 92844G 10 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transiti |
|
| November 2, 2022 |
INNOVAQOR, INC. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 INNOVAQOR, INC. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 November 2, 2022 VIA EDGAR Kyle Wiley Staff Attorney Office of Technology Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: InnovaQor, Inc. (the ?Company?) Offering Statement on Form 1-A (the ?Offering Statement?) Filed October 27, 2022 File No. 024-1 |
|
| October 27, 2022 |
SUBSCRIPTION AGREEMENT InnovaQor, Inc. NOTICE TO INVESTORS Exhibit 4.1 SUBSCRIPTION AGREEMENT InnovaQor, Inc. NOTICE TO INVESTORS The securities of InnovaQor, Inc., a Nevada corporation (the ?Company?), to which this Subscription Agreement relates, represent an investment that involves a high degree of risk, suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investments. Invest |
|
| October 27, 2022 |
As filed with the Securities and Exchange Commission on October 27, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated October 27, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the ?SEC?). |
|
| October 27, 2022 |
Exhibit 12.1 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road ? Suite 107-762 Flower Mound, Texas 75022 940-367-6154 October 27, 2022 InnovaQor, Inc. 400 South Australian Avenue Suite 800 West Palm Beach, Florida 33401 Re: Offering Statement on Form 1-A Ladies and Gentlemen: We have been requested by InnovaQor, Inc., a Nevada corporation (the ?Company?), to furnish you with our opinion as to the matte |
|
| October 27, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use of our report dated July 29, 2022, on the financial statements of InnovaQor, Inc. (formerly known as VisualMED Clinical Solutions Corporation) as of December 31, 2021 and 2020 and for the years then ended included herein on the Regulation A Offering Statement of InnovaQor, Inc. on Form 1-A. We also c |
|
| October 20, 2022 |
PRE 14C 1 formpre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement INNOVAQOR, |
|
| September 7, 2022 |
CORRESP 1 filename1.htm J. Thomas Cookson Partner Shutts & Bowen LLP 200 South Biscayne Boulevard Suite 4100 Miami, Florida 33131 DIRECT (305) 379-9141 FAX (305) 347-7767 EMAIL [email protected] September 7, 2022 VIA EDGAR Ms. Olivia Bobes United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: InnovaQor, Inc. Registration Statement on Form 10-12G Filed July |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 88-0436055 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N |
|
| August 16, 2022 |
CORRESP 1 filename1.htm J. Thomas Cookson Partner Shutts & Bowen LLP 200 South Biscayne Boulevard Suite 4100 Miami, Florida 33131 DIRECT (305) 379-9141 FAX (305) 347-7767 EMAIL [email protected] August 16, 2022 VIA EDGAR Ms. Olivia Bobes United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: InnovaQor, Inc. Amendment No. 1 to Registration Statement on Form 1 |
|
| July 29, 2022 |
EXHIBIT 21 NAME JURISDICTION OF ORGANIZATION Health Technology Solutions, Inc. Florida ClinLab, Inc. Florida Medical Mime, Inc. Florida Advanced Molecular Services Group, Inc. Florida Genomas, Inc. Delaware CollabRx, Inc. Delaware |
|
| July 29, 2022 |
Exhibit 3.1(i) ARTICLES OF INCORPORATION OF ANCONA MINING CORPORATION ***** FIRST The name of the corporation is ANCONA MINING CORPORATION. SECOND Its principal office in the state of Nevada is located at 5844 South Pecos Road Suite D. Las Vegas Nevada 89120 The name and address of its resident agent is Pacific Corporate Services, 5844 South Pecos Road, Suite D, Las Vegas, Nevada 89120. THIRD The |
|
| July 29, 2022 |
Exhibit 2.1 ACQUISITION AGREEMENT This Acquisition Agreement (?Agreement?, transaction herein known as the ?Acquisition?) is made and entered into as of May 12, 2021 (the ?Effective Date?), by and between Rennova Health, Inc., a Delaware corporation, with its principal office at, 400 S. Australian Ave. 8th Floor. West Palm Beach, FL 33401 (?Rennova? or ?RNI?) and VisualMed Clinical Solutions, Corp |
|
| July 29, 2022 |
Exhibit 3.1(ii) BYLAWS OF INNOVAQOR, INC. I. SHAREHOLDER?S MEETING. .01 Annual Meetings. The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may come before it shall be held at the registered office of the Corporation, or such other places, either within or without the State of Nevada, as may be designated by the notic |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 88-0436055 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 400 S. Australi |
|
| July 29, 2022 |
Exhibit 10.1 CONSULTING AGREEMENT between Epizon Limited and Gerard Dab, CEO of VisualMED Clinical Solutions, Corp. THIS AGREEMENT is entered into and is effective as of the May 2nd 2021, by and between Epizon Limited, a Bahamas based Company with an address at Suite 104A, Saffrey Square, Bank Lane, PO Box N-9306, (the “Company”), and, Gerard Dab, CEO of VisualMED Clinical Solutions, Corp., a Pink |
|
| April 29, 2022 |
InnovaQor, Inc. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 InnovaQor, Inc. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 April 29, 2022 VIA EDGAR Division of Corporation Finance Office of Technology Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Olivia Bobes, Matthew Derby, Joseph Kempf and Kathryn Jacobson Re: InnovaQor, Inc. Request to Withdraw Registration Statement on Form 10, as amended File |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 88-0436055 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N |
|
| April 20, 2022 |
J. Thomas Cookson Partner Shutts & Bowen LLP 200 South Biscayne Boulevard Suite 4100 Miami, Florida 33131 DIRECT (305) 379-9141 FAX (305) 347-7767 EMAIL [email protected] April 20, 2022 VIA EDGAR Ms. Olivia Bobes United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: InnovaQor, Inc. Registration Statement on Form 10 Filed March 3, 2022 File No. 000-33191 Dea |
|
| April 20, 2022 |
Exhibit 2.1 ACQUISITION AGREEMENT This Acquisition Agreement (?Agreement?, transaction herein known as the ?Acquisition?) is made and entered into as of May 12, 2021 (the ?Effective Date?), by and between Rennova Health, Inc., a Delaware corporation, with its principal office at, 400 S. Australian Ave. 8th Floor. West Palm Beach, FL 33401 (?Rennova? or ?RNI?) and VisualMed Clinical Solutions, Corp |
|
| April 20, 2022 |
Articles of Incorporation, as amended, of InnovaQor, Inc. Exhibit 3.1(i) ARTICLES OF INCORPORATION OF ANCONA MINING CORPORATION ***** FIRST The name of the corporation is ANCONA MINING CORPORATION. SECOND Its principal office in the state of Nevada is located at 5844 South Pecos Road Suite D. Las Vegas Nevada 89120 The name and address of its resident agent is Pacific Corporate Services, 5844 South Pecos Road, Suite D, Las Vegas, Nevada 89120. THIRD The |
|
| April 20, 2022 |
Consulting Agreement, dated as of May 2, 2021, between Epizon Limited and Gerard Dab. Exhibit 10.1 CONSULTING AGREEMENT between Epizon Limited and Gerard Dab, CEO of VisualMED Clinical Solutions, Corp. THIS AGREEMENT is entered into and is effective as of the May 2nd 2021, by and between Epizon Limited, a Bahamas based Company with an address at Suite 104A, Saffrey Square, Bank Lane, PO Box N-9306, (the ?Company?), and, Gerard Dab, CEO of VisualMED Clinical Solutions, Corp., a Pink |
|
| March 3, 2022 |
Subsidiaries of the Registrant EXHIBIT 21 NAME JURISDICTION OF ORGANIZATION Health Technology Solutions, Inc. Florida ClinLab, Inc. Florida Medical Mime, Inc. Florida Advanced Molecular Services Group, Inc. Florida Genomas, Inc. Delaware CollabRx, Inc. Delaware |
|
| March 3, 2022 |
Articles of Incorporation, as amended, of InnovaQor, Inc. Exhibit 3.1(i) |
|
| March 3, 2022 |
Exhibit 3.1(ii) BYLAWS OF INNOVAQOR, INC. I. SHAREHOLDER’S MEETING. .01 Annual Meetings. The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may come before it shall be held at the registered office of the Corporation, or such other places, either within or without the State of Nevada, as may be designated by the notic |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 88-0436055 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 400 S. Australi |
|
| March 3, 2022 |
Exhibit 2.1 |
|
| February 18, 2022 |
InnovaQor, Inc. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 RW 1 formrw.htm InnovaQor, Inc. 400 South Australian Avenue, Suite 800 West Palm Beach, Florida 33401 February 18, 2022 VIA EDGAR Division of Corporation Finance Office of Technology Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jan Woo, Alexandra Barone, Joseph Kempf and Kathryn Jacobson Re: InnovaQor, Inc. Request to Withdraw Registration Statement on Form 10 |
|
| December 22, 2021 |
Exhibit 3.1(ii) BYLAWS OF INNOVAQOR, INC. I. SHAREHOLDER?S MEETING. .01 Annual Meetings. The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may come before it shall be held at the registered office of the Corporation, or such other places, either within or without the State of Nevada, as may be designated by the notic |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 InnovaQor, Inc. (Exact name of registrant as specified in its charter) Nevada 88-0436055 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 400 S. Australi |
|
| December 22, 2021 |
Exhibit 2.1 |
|
| December 22, 2021 |
Subsidiaries of the Registrant EX-21 88 ex21.htm EXHIBIT 21 NAME JURISDICTION OF ORGANIZATION Health Technology Solutions, Inc. Florida ClinLab, Inc. Florida Medical Mime, Inc. Florida Advanced Molecular Services Group, Inc. Florida Genomas, Inc. Delaware CollabRx, Inc. Delaware |
|
| December 22, 2021 |
Articles of Incorporation, as amended, of InnovaQor, Inc. Exhibit 3.1(i) |
|
| May 14, 2008 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLUTIONS |
|
| March 6, 2008 |
S-8 1 c52641s8.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Registration Statement Under The Securities Act of 1933, as amended. VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in charter.) Nevada 88-0436055 (State or other jurisdiction or organization) (I.R.S. Employer Identification Number) VISUALMED CLINICAL SOLUTIONS CORP. 1035 Laurier W. Sui |
|
| March 6, 2008 |
EX-4.1 2 c52641ex4-1.htm Exhibit 4.1 VISUALMED CLINICAL SOLUTIONS CORP. FEBRUARY 2008 NONQUALIFIED STOCK OPTION PLAN ARTICLE I Purpose of Plan This NONQUALIFIED STOCK OPTION PLAN (the “Plan”) of VISUALMED CLINICAL SOLUTIONS CORP. (the “Company”) for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, |
|
| March 6, 2008 |
FORM OF NON QUALIFIED STOCK OPTION AGREEMENT EX-4.2 3 c52641ex4-2.htm Exhibit 4.2 Number of Shares: Date of Grant: FORM OF NON QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made this day of , 20, between (the “Optionee”), and VISUALMED CLINICAL SOLUTIONS CORP., a Nevada corporation (the “Company”). 1. Grant of Option. The Company, pursuant to the provisions of The FEBRUARY 2008 VISUALMED CLINICAL SOLUTIONS CORP. Nonqualified Stock Option Plan ( |
|
| February 14, 2008 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31st, 2007 c TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLUT |
|
| November 20, 2007 |
EX-4.1 2 c51348ex4-1.htm Exhibit 4.1 VISUALMED CLINICAL SOLUTIONS CORP. NOVEMBER 2007 NONQUALIFIED STOCK OPTION PLAN ARTICLE I Purpose of Plan This NONQUALIFIED STOCK OPTION PLAN (the “Plan”) of VISUALMED CLINICAL SOLUTIONS CORP. (the “Company”) for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, |
|
| November 20, 2007 |
FORM OF NON QUALIFIED STOCK OPTION AGREEMENT EX-4.2 3 c51348ex4-2.htm Exhibit 4.2 Number of Shares: Date of Grant: FORM OF NON QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made this day of , 20, between (the “Optionee”), and VISUALMED CLINICAL SOLUTIONS CORP., a Nevada corporation (the “Company”). 1. Grant of Option. The Company, pursuant to the provisions of The NOVEMBER 2007 VISUALMED CLINICAL SOLUTIONS CORP. Nonqualified Stock Option Plan ( |
|
| November 20, 2007 |
S-8 1 c51348s-8.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Registration Statement Under The Securities Act of 1933, as amended. VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in charter.) Nevada 88-0436055 (State or other jurisdiction or organization) (I.R.S. Employer Identification Number) VISUALMED CLINICAL SOLUTIONS CORP. 1035 Laurier W. Su |
|
| November 14, 2007 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30th, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLU |
|
| November 8, 2007 |
8-K 1 c511148k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2007 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 (State or other jurisdiction o |
|
| September 28, 2007 |
8-K 1 c505488-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2007 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 (State or other jurisdictio |
|
| September 28, 2007 |
U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2007 OR c TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-33191 VISUALMED CLINICAL SOLUTIONS CORP. (N |
|
| July 24, 2007 |
EX-4.1 2 c49530ex4-1.htm Exhibit 4.1 VISUALMED CLINICAL SOLUTIONS CORP. JULY 2007 NONQUALIFIED STOCK OPTION PLAN ARTICLE I Purpose of Plan This NONQUALIFIED STOCK OPTION PLAN (the “Plan”) of VISUALMED CLINICAL SOLUTIONS CORP. (the “Company”) for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, cons |
|
| July 24, 2007 |
FORM OF NON QUALIFIED STOCK OPTION AGREEMENT EX-4.2 3 c49530ex4-2.htm Exhibit 4.2 Number of Shares: Date of Grant: FORM OF NON QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made this day of , 20, between (the “Optionee”), and VISUALMED CLINICAL SOLUTIONS CORP., a Nevada corporation (the “Company”). 1. Grant of Option. The Company, pursuant to the provisions of The JULY 2007 VISUALMED CLINICAL SOLUTIONS CORP. Nonqualified Stock Option Plan (the |
|
| July 24, 2007 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Registration Statement Under The Securities Act of 1933, as amended. VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in charter.) Nevada 88-0436055 (State or other jurisdiction or organization) (I.R.S. Employer Identification Number) VISUALMED CLINICAL SOLUTIONS CORP. 1035 Laurier W. Suite 200 Montreal, Qu |
|
| July 23, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19th, 2007 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 (State or other jurisdiction of incorporation) (Co |
|
| May 14, 2007 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31st, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLUTION |
|
| May 9, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9th, 2007 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 (State or other jurisdiction of incorporation) (Comm |
|
| March 22, 2007 |
FORM OF NON QUALIFIED STOCK OPTION AGREEMENT EX-4.2 3 c47561ex4-2.htm Exhibit 4.2 Number of Shares: Date of Grant: FORM OF NON QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made this day of , 20, between (the “Optionee”), and VISUALMED CLINICAL SOLUTIONS CORP., a Nevada corporation (the “Company”). 1. Grant of Option. The Company, pursuant to the provisions of The MARCH 2007 VISUALMED CLINICAL SOLUTIONS CORP. Nonqualified Stock Option Plan (the |
|
| March 22, 2007 |
S-8 1 c47561s8.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Registration Statement Under The Securities Act of 1933, as amended. VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in charter.) Nevada 88-0436055 (State or other jurisdiction or organization) (I.R.S. Employer Identification Number) VISUALMED CLINICAL SOLUTIONS CORP. 1035 Laurier W. Sui |
|
| March 22, 2007 |
EX-4.1 2 c47561ex4-1.htm Exhibit 4.1 VISUALMED CLINICAL SOLUTIONS CORP. MARCH 2007 NONQUALIFIED STOCK OPTION PLAN ARTICLE I Purpose of Plan This NONQUALIFIED STOCK OPTION PLAN (the “Plan”) of VISUALMED CLINICAL SOLUTIONS CORP. (the “Company”) for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, con |
|
| February 14, 2007 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31st, 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to. Commission file number: 000-33191 VISUALMED CLINICAL SOLU |
|
| December 21, 2006 |
December 21, 2006 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 7, 2006 |
December 7, 2006 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 13, 2006 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ? September 30th 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOL |
|
| October 4, 2006 |
FORM OF NON QUALIFIED STOCK OPTION AGREEMENT EX-4 3 ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Number of Shares: Date of Grant: FORM OF NON QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made this day of , 20, between (the “Optionee”), and VISUALMED CLINICAL SOLUTIONS CORP., a Nevada corporation (the “Company”). 1. Grant of Option. The Company, pursuant to the provisions of The OCTOBER 2006 VISUALMED CLINICAL SOLUTIONS CORP. Nonqualified Stock Option Pla |
|
| October 4, 2006 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Registration Statement Under The Securities Act of 1933, as amended. VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in charter.) Nevada 88-0436055 (State or other jurisdiction or organization) (I.R.S. Employer Identification Number) VISUALMED CLINICAL SOLUTIONS CORP. 1035 Laurier W. Suite 200 Montreal, Qu |
|
| October 4, 2006 |
Exhibit 4.1 VISUALMED CLINICAL SOLUTIONS CORP. OCTOBER 2006 NONQUALIFIED STOCK OPTION PLAN ARTICLE I Purpose of Plan This NONQUALIFIED STOCK OPTION PLAN (the ?Plan?) of VISUALMED CLINICAL SOLUTIONS CORP. (the ?Company?) for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accountant, consultant or advisor, is |
|
| September 28, 2006 |
10-K 1 a42842.htm VISUALMED CLINICAL SOLUTIONS CORP. U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2006 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file n |
|
| September 28, 2006 |
VisualMED Clinical Solutions CORPORATION EMPLOYMENT AGREEMENT EX-10 4 ex10-12.htm EXHIBIT 10.12 VisualMED Clinical Solutions CORPORATION EMPLOYMENT AGREEMENT AGREEMENT, dated as of this first day of April 1, 2006, by and between VisualMED Clinical Solutions Corp., a Nevada Corporation, with its principal offices located at 1035 rue Laurier, Montreal, Quebec, Canada H2V 2L1 (“SOLUTIONS”), and Larry Kurlender (“KURLENDER”), residing at 15 Cressy, Montreal, Que |
|
| June 26, 2006 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2006 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 (State or other jurisdiction of incorporation) (Comm |
|
| June 26, 2006 |
VisualMED Expands Board of Directors VisualMED Expands Board of Directors Mr. Chris Marcolefas to sit as Independent MONTREAL-(BUSINESS WIRE) June 23, 2006-VisualMED Clinical Solutions Corp. (the ?Company?) (OTC BB: VMCS - News) is pleased to announce the appointment of Mr. Chris Marcolefas to the Board of Directors of the Company where he will sit as an independent member, as well as take on the responsibilities of chairman of the a |
|
| May 18, 2006 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ? March 31st 2006 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLUTIO |
|
| April 25, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2006 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 (State or other jurisdiction of incorporation) (Com |
|
| April 10, 2006 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a41775.htm VISUALMED CLINICAL SOLUTIONS CORP. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2006 VisualMED Clinical Solutions Corp. (Exact name of registrant as specified in its charter) NEVADA 000-33191 88-0436055 |
|
| April 10, 2006 |
VisualMED signs 3.4 million deal for private network to link private clinics and labs in Quebec EXHIBIT 99.1 PRESS RELEASE VisualMED signs 3.4 million deal for private network to link private clinics and labs in Quebec Shortage of facilities and a rapidly aging population drives adoption of new technology in the private sector MONTREAL-(BUSINESS WIRE) April 10, 2006-VisualMED Clinical Solutions Corp. (the ?Company?) (OTC BB: VMCS - News) announces today that it has entered into an agreement |
|
| April 6, 2006 |
VisualMED signs $9 million deal to implement private hospital EXHIBIT 99.1 PRESS RELEASE VisualMED signs $9 million deal to implement private hospital Healthcare reform opens new opportunity for VisualMED MONTREAL?(BUSINESS WIRE)? April 5th, 2006-VisualMED Clinical Solutions Corp. (the ?Company?) (OTC BB: VMCS - News) announces today that it will be providing an expanded and comprehensive clinical information system that includes a homecare post-operative mo |
|
| April 6, 2006 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a41761.htm VISUALMED CLINICAL SOLUTIONS CORP. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2006 VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 000-33191 88-0436055 |
|
| March 2, 2006 |
SECURITIES AND EXCHANGE COMMISSION S-8 1 a41459.htm VISUALMED CLINICAL SOLUTIONS CORP. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Registration Statement Under The Securities Act of 1933, as amended. VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in charter.) Nevada 88-0436055 (State or other jurisdiction or organization) (I.R.S. Employer Identification Number) VISUALMED CLINICAL SO |
|
| March 2, 2006 |
EX-4 2 ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 VISUALMED CLINICAL SOLUTIONS CORPORATION 2006 NONQUALIFIED STOCK OPTION PLAN ARTICLE I Purpose of Plan This NONQUALIFIED STOCK OPTION PLAN (the “Plan”) of VISUALMED CLINICAL SOLUTIONS CORPORATION (the “Company”) for persons employed or associated with the Company, including without limitation any employee, director, general partner, officer, attorney, accou |
|
| March 2, 2006 |
EX-4 3 ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Number of Shares: Date of Grant: FORM OF NON QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made this day of , 20, between (the “Optionee”), and VISUALMED CLINICAL SOLUTIONS CORPORATION, a Nevada corporation (the “Company”). 1. Grant of Option. The Company, pursuant to the provisions of The 2006 VISUALMED CLINICAL SOLUTIONS CORPORATION Nonqualified Stock Option |
|
| February 24, 2006 |
WARRANT TO PURCHASE SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE EX-10 6 ex10-8.htm EXHIBIT 10.8 THE SECURITIES REPRESENTED HEREBY MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144(K), OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATI |
|
| February 24, 2006 |
Registration No. 333-125348 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM SB-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amendment No. 2 VISUALMED CLINICAL SOLUTIONS CORPORATION (Name of small business issuer in its charter) Nevada (State or other jurisdiction of organization) 8060 (Primary Standard Industrial Classification Code) 88-0436055 (IRS Em |
|
| February 15, 2006 |
[VISUALMED CLINICAL SOLUTIONS CORP. LETTERHEAD] [VISUALMED CLINICAL SOLUTIONS CORP. LETTERHEAD] February 15, 2006 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Kathleen Collins Accounting Branch Chief Re: VisualMED Clinical Solutions Corp. Form 10-KSB for fiscal year ended June 30, 2005 Filed September 29, 2005 Form 10-QSB for fiscal quarter ended September 30, 2005 Filed November 10, 2005 File # 00 |
|
| February 15, 2006 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ? December 31, 2005 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLUT |
|
| February 15, 2006 |
U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB/A Amendment No. 1 U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2005 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-33191 VISUALMED CLINICAL |
|
| February 15, 2006 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ? September 30, 2005 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUA |
|
| December 8, 2005 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2004 VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 000-33191 88-0436055 (State or other jurisdiction of incorporation) |
|
| December 8, 2005 |
Registration No. 333-125348 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM SB-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amendment No. 1 VISUALMED CLINICAL SOLUTIONS CORPORATION (Name of small business issuer in its charter) Nevada (State or other jurisdiction of organization) 8060 (Primary Standard Industrial Classification Code) 88-0436055 (IRS Em |
|
| November 15, 2005 |
VisualMED System Live at Southwest Regional Rehabilitation Center EXHIBIT 99.1 PRESS RELEASE VisualMED System Live at Southwest Regional Rehabilitation Center MONTREAL-(BUSINESS WIRE)-Nov. 7, 2005-VisualMED Clinical Solutions Corporation ("The Company")(NASDAQ OTC BB:VMCS - News) announces that the implementation of its flagship Clinical Information System at Southwest Regional Rehabilitation Center of Battle Creek, Michigan has now been completed. The hospital- |
|
| November 15, 2005 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a40826.htm VISUALMED UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2005 VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 000-33191 88-0436055 (State or other juris |
|
| November 10, 2005 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ? September 30, 2005 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-33191 VISUALMED CLINICAL SOLU |
|
| October 14, 2005 |
EXHIBIT 99.1 Contact: VisualMED Clinical Solutions Corp. Barry Scharf Chief Operating Officer (514) 274-1115 Annual reports concludes an very active year. MONTREAL - October 5, 2005 - VisualMED Clinical Solutions Corp. (NASDAQ OTC BB: VMCS - News) On September 29, 2005, VisualMed Clinical Solutions Corp. (the ?Company?) filed its annual report for the fiscal year ended June 30, 2005. At June 30, 2 |
|
| October 14, 2005 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K/A 1 a40636.htm VISUALMED CLINICAL SOLUTIONS CORP. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2005 VISUALMED CLINICAL SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 000-33191 88-0 |
|
| September 29, 2005 |
ANCONA MINING CORPORATION EMPLOYMENT AGREEMENT EX-10 4 ex10-9.htm EXHIBIT 10.9 ANCONA MINING CORPORATION EMPLOYMENT AGREEMENT AGREEMENT, dated as of this 25th day of October 2004, by and between ANCONA MINING CORP., a Nevada Corporation, with its principal offices located at 391A rue Laurier, Montreal, Quebec, Canada H2V 2K3 (“ANCONA”), and Gerard Dab (“DAB”), residing at 267 Metcalfe Ave., Westmount, Quebec, H3Z 2H6. This Employment Agreement |
|
| September 29, 2005 |
U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB U.S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2005 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-33191 VISUALMED CLINICAL SOLUTIONS CORP. (N |
|
| September 29, 2005 |
ANCONA MINING CORPORATION EMPLOYMENT AGREEMENT ANCONA MINING CORPORATION EMPLOYMENT AGREEMENT AGREEMENT, dated as of this 25th day of October 2004, by and between ANCONA MINING CORP. |
|
| September 29, 2005 |
ANCONA MINING CORPORATION EMPLOYMENT AGREEMENT ANCONA MINING CORPORATION EMPLOYMENT AGREEMENT AGREEMENT, dated as of this 25th day of October 2004, by and between ANCONA MINING CORP. |
|
| August 19, 2005 |
8-K 1 vmcs8k81905.htm VISUALMED CLINICAL SOLUTIONS CORP. FORM 8-K FOR AUGUST 18, 2005. ===================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 18, |
|
| August 8, 2005 |
EX-10.3 4 exh103.htm SERIES A WARRANT - NUMBER OF SHARES: 400,438. Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE ST |
|
| August 8, 2005 |
EX-10.7 8 exh107.htm REGISTRATION RIGHTS AGREEMENT. Exhibit 10.7 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of March 24, 2005, by and among VisualMed Clinical Solutions Corporation, a Nevada corporation (the "Company"), and the purchasers listed on Schedule I hereto (the "Purchasers"). This Agreement is being entered into pursuan |
|
| August 8, 2005 |
MEMORANDUM OF A CONSULTANT AGREEMENT EX-10.1 2 exh101.htm MEMORANDUM OF A CONSULTANT AGREEMENT. Exhibit 10.1 MEMORANDUM OF A CONSULTANT AGREEMENT THIS AGREEMENT is made as of the March 7, 2005. B E T W E E N : Claude Pellerin, businessman, businessman, having a business place at 460 Saint-Gabriel, suite 21, city of Montreal, province of Québec, H2Y 2Z9 (Hereinafter referred to as the "Consultant") - and - VisualMED Clinical Solutions |
|
| August 8, 2005 |
MEMORANDUM OF A RETAINER AGREEMENT FOR LEGAL SERVICES EX-10.2 3 exh102.htm MEMORANDUM OF A RETAINER AGREEMENT. Exhibit 10.2 MEMORANDUM OF A RETAINER AGREEMENT FOR LEGAL SERVICES THIS AGREEMENT is made as of the March 7, 2005. B E T W E E N : Hovington Pellerin Simard, general partnership, having a business place at 460 Saint-Gabriel, suite 21, city of Montreal, province of Québec, H2Y 2Z9 (Hereinafter referred to as the "Attorneys") - and - VisualMED |
|
| August 8, 2005 |
EX-10.5 6 exh105.htm SERIES A WARRANT - NUMBER OF SHARES: 1,321,759. Exhibit 10.5 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE |
|
| August 8, 2005 |
SB-2/A 1 vmcscsb2a1.htm VISUALMED CLINICAL SOLUTIONS CORPORATION FORM SB-2/A-1. Registration No. 333-125348 ==================================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM SB-2/A-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VISUALMED CLINICAL SOLUTIONS CORPORATION (Name of small business issuer in it |
|
| August 8, 2005 |
EX-10.8 9 exh108.htm FINDER'S AGREEMENT. Exhibit 10.8 FINDERS AGREEMENT This Agreement (the "Agreement") is entered into on this 21st day of March, 2005, by and between Stephane Solis, ("Solis" or the "Finder"), and VisualMed Clinical Solutions Corporation, (the "Issuer" or the "Company"). 1. THE PARTIES 1.1 Each party executing this Agreement represents to the other party that it has full and com |
|
| August 8, 2005 |
COMMON STOCK PURCHASE AGREEMENT EX-10.6 7 exh106.htm COMMON STOCK PURCHASE AGREEMENT. Exhibit 10.6 COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT dated as of March 24, 2005 (this "Agreement") by and between VisualMed Clinical Solutions Corporation, a Nevada corporation (the "Company"), and the purchasers listed on Exhibit A attached hereto (each a "Purchaser" and collectively, the "Purchasers"), for the pur |
|
| August 8, 2005 |
EX-10.4 5 exh104.htm SERIES A WARRANT - NUMBER OF SHARES: 553,370. Exhibit 10.4 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE ST |
|
| July 20, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB/A-2 10QSB/A 1 vms10qsba2123104.htm AMENDMENT TO THE FORM 10-QSB FOR VISUALMED ================================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB/A-2 [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2004 |
|
| June 14, 2005 |
Business leaders and Dean of Medical School join Advisory Board Exhibit 99.1 Business leaders and Dean of Medical School join Advisory Board MONTREAL, June 8, 2005 - VisualMED Clinical Solutions Corp. (NASDAQ BB VMCS) announces today the appointments of three new members to serve on its Board of Advisors. The Board is made up of independent business and professional leaders who assist the company in developing and implementing corporate policy. The Board plays |
|
| June 14, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K for VisualMed Clinical Solutions Corp. ======================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2005 VisualMED Clinical Solutions Corp |
|
| May 31, 2005 |
As filed with the Securities and Exchange Commission on . Registration No. =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - - FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VISUALMED CLINICAL SOLUTIONS CORPORATION (Name of small business issuer in its charter) Nevada 8060 88-0436055 (State or |
|
| May 16, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB 10QSB 1 vms10qsb33105.htm FIRST QUARTER REPORT FOR VISUALMED CLINICAL SOLUTIONS CORP. ================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2005 OR [ ] Tran |
|
| March 4, 2005 |
Exhibit 99.1 Company and Solution Profiles VisualMED Clinical Solutions Corp. has signed a cooperation agreement with engineering firm SNC Lavalin of Montreal, Canada. This agreement sets out the terms of how SNC Lavalin and VisualMED will team on a project basis to install new-generation software for Clinical Information Systems. SNC Lavalin, one of the world's largest publicly-traded engineering |
|
| March 4, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB =================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [ x ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2004 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-33191 VISUALMED CLINICAL SOLUTIONS CORP. |
|
| March 4, 2005 |
=================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 3, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB =================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [ x ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2004 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-33191 VISUALMED CLINICAL SOLUTIONS CORP. |
|
| February 22, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB =========================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [ x ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2004 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-33191 VISUALMED CLINICAL SOLUTIONS CORP. |
|
| February 22, 2005 |
EX-3 2 exh33.htm AMENDMENT TO THE ARTICLES OF INCORPORATION Exhibit 3.3 DEAN HELLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4299 (775) 684-5708 Website: secretaryofstate.biz Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) Important: read attached instructions before completing form. ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Ar |
|
| February 15, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q For the period ended December 31, 2004. [ ] Transition Report on Form 10-K. [ ] Transition Report on Form 20-F. [ ] Transition Report on Form 11-K. [ ] Transition Report on Form 10-Q. For the Transition Period Ended: If the notifica |
|
| February 10, 2005 |
Exhibit 99.1 Michigan hospital purchases the VisualMED Clinical Information System. Southwest Regional Rehabilitation Center will implement in Q2 2005. MONTREAL, February 9, 2005 - VisualMED Clinical Solutions Corp. (VMCS OTCBB) announces today that it has successfully concluded the sale of its flagship product, the VisualMED Clinical Information System (CIS), to Southwest Regional Rehabilitation |
|
| February 10, 2005 |
=================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 25, 2005 |
========================================================================= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 25, 2005 |
New market for VisualMED in North Africa EX-99.1 2 exb991.htm PRESS RELEASE. New market for VisualMED in North Africa Government agency helps planning pilot project MONTREAL, January 24, 2005 - VisualMED Clinical Solutions Corp. (OTCBB VMCS) announces today that its European distribution partners are moving ahead with a planned pilot implementation in one of Tunisia's most modern hospitals, in partnership with a leading Tunisian medical |
|
| January 13, 2005 |
=================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 13, 2005 |
FIRST COMMERCIAL CONTRACT FOR NEW SCOPE- NOTES (C) PRODUCT Exhibit 99.1 FIRST COMMERCIAL CONTRACT FOR NEW SCOPE- NOTES (C) PRODUCT New ambulatory care module sold to Sir Mortimer B. Davis Jewish General Hospital of Montreal MONTREAL, January 13, 2005 - VisualMED Clinical Solutions Corp.(VMCS OTCBB), announced today that the first sale of one of its series of ambulatory care modules, Scope-Notes(C), was completed by its Canadian distributor, Medicool Healt |
|
| January 6, 2005 |
VisualMED Clinical Solutions Corp. Exhibit 99.1 PRESS RELEASE From: VisualMED Clinical Solutions Corp. Contact: Barry Scharf, COO Tel.: (514) 274-1115 [email protected] VisualMED Clinical Solutions Corp. successfully implements new upgrade of its Clinical Information System MONTREAL, January 6, 2005 - VisualMED Clinical Solutions Corp. (VMCS OTCBB) announces today that it has successfully completed the implementation o |
|
| January 6, 2005 |
=================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 27, 2004 |
VISUALMED CLINICAL SOLUTIONS CORP sees faster growth in market for hospital informatics EX-99.1 2 exh991.htm PRESS RELEASE. Exhibit 99.1 VISUALMED CLINICAL SOLUTIONS CORP sees faster growth in market for hospital informatics Shareholders Approve of Name Change MONTREAL, DECEMBER 14, 2004 - VisualMED Clinical Solutions Corporation (OTC BB VMCS), is pleased to report that its shareholders have recently agreed to change the name of the company following the acquisition on October 13, 20 |
|
| December 27, 2004 |
8-K 1 amc8k122304.htm ANCONA MINING CORPORATION FORM 8-K FOR DECEMBER 23, 2004. =================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 23, 2004 AN |
|
| November 17, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB =================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2004 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number:000-33191 ANCONA MINES CORPORATION (Exact name of registrant as specified in its charter) Nevada 88-0436055 (State of other jurisdiction of incorporation or organization) (IRS Employer Identification Number) 1035 Laurier St. |
|
| November 16, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-Q 1 amc12b25.htm ANCONA MINING CORPORATION FORM 12B-25 (10-QSB SEPTEMBER 2004) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q For the period ended September 30, 2004. [ ] Transition Report on Form 10-K. [ ] Transition Report on Form 20-F. [ ] Transition Report on Form 11-K |
|
| October 29, 2004 |
SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934. |
|
| October 28, 2004 |
=================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 28, 2004 |
Exhibit 99.1 ANCONA ACQUIRES ASSETS AND DISTRIBUTION RIGHTS FROM VISUALMED CLINICAL SYSTEMS. Company enters the fast growing field of hospital clinical management solutions MONTREAL, OCTOBER 26, 2004 - Ancona Mining Corporation (OTCBB: ANAG) is pleased to announce that it has completed the acquisition of key commercial assets from VisualMED Clinical Systems Corp. of Montreal and will become active |
|
| October 19, 2004 |
Entry into a Material Definitive Agreement =================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 19, 2004 |
EX-10.1 2 exh101.htm Exhibit 10.1 AGREEMENT AGREEMENT dated September 23, 2004 between VisualMed Clinical Systems Corporation, a corporation incorporated under the laws of Nevada, hereinafter referred to as the "Seller", and Ancona Mining Corporation, a Nevada corporation hereinafter referred to as the "Buyer". This Agreement sets forth the terms and conditions upon which the Seller is conveying t |
|
| October 19, 2004 |
PRE 14C 1 amcsch14cpre.htm ANCONA MINING CORP. SCHEDULE 14C - PRELIMINARY SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934. Filed by the Registrant [X] Filed by Party other than the Registrant [ ] [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only [as permitted by Rule 14a-6(e)(2)] [ ] Definitive Inf |
|
| October 8, 2004 |
========================================================================= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 22, 2004 |
FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C.20549 =================================================================================== FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 13, 2004 |
QUARTERLY REPORT ON FORM 10QSB FOR THE QUARTER ENDED DECEMBER 31, 2003 QUARTERLY REPORT ON FORM 10QSB FOR THE QUARTER ENDED DECEMBER 31, 2003 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 16, 2003 |
FORM 10-KSB/A-1 SECURITIES AND EXCHANGE COMMISSION Washington, D. C.20549 10KSB/A 1 aml10ksba1.htm AMENDMENT TO THE FORM 10-KSB FOR THE YEAR ENDING JUNE 30, 2003 FOR ANCONA MINING CORPORATION FORM 10-KSB/A-1 SECURITIES AND EXCHANGE COMMISSION Washington, D. C.20549 [ x ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2003 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
|
| September 5, 2003 |
Youâve Exceeded the SECâs Traffic Limit EX-99.1 6 exh991.htm Exhibit 99.1 ANCONA MINING CORPORATION CHARTER - AUDIT COMMITTEE Committee Role The committee's role is to act on behalf of the board of directors and oversee all material aspects of the company's reporting, control, and audit functions, except those specifically related to the responsibilities of another standing committee of the board. The audit committee's role includes a p |
|
| September 5, 2003 |
FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C.20549 10KSB 1 amc10k63003.htm FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C.20549 [ x ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2003 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-33191 ANCONA MINING |
|
| September 5, 2003 |
ANCONA MINING CORPORATION CODE OF ETHICS Exhibit 14.1 Exhibit 14.1 ANCONA MINING CORPORATION CODE OF ETHICS TOPICS 1. Statement of Policy 2. Implementation and Enforcement 3. Relations with Competitors and Other Third Parties 4. Insider Trading, Securities Compliance and Public Statements 5. Financial Reporting 6. Human Resources 7. Environmental, Health and Safety 8. Conflicts of Interest 9. International Trade 10. Government Relations |
|
| September 5, 2003 |
ANCONA MINING CORPORATION DISCLOSURE COMMITTEE EX-99.2 7 exh992.htm Exhibit 99.2 ANCONA MINING CORPORATION DISCLOSURE COMMITTEE CHARTER Disclosure Policy All financial disclosures made by the Corporation to its security holders or the investment community should (i) be accurate, complete and timely, (ii) fairly present, in all material respects, the Corporation's financial condition, results of operations and cash flows, and (iii) meet any oth |
|
| May 13, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [x] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2003 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to COMMISSION FILE NUMBER 333-94835 ANCONA MINING CORP |
|
| May 5, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB 10QSB 1 anag033103.htm MARCH 31 2003 Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [x] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2003 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to COMMISSION F |
|
| February 11, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB 10QSB 1 anag1231.htm ANCONA DEC 31 2002 10QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [x] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2002 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to CO |
|
| November 12, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB 10QSB 1 ami93010q.htm FORM 10-QSB FOR ANCONA MINING CORPORATION ================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [x] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2002 OR [ ] Transition Report Pursu |
|
| November 5, 2002 |
8-K/A 1 ancona8ka.htm AMENDMENT TO THE FORM 8-K FOR ANCONA MINING CORPORATION ================================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report November 4, 2002 ANCONA MINING CORPORATION (Exact name of registran |
|
| November 5, 2002 |
EX-16 3 exh161.htm LETTER FROM WILLIAMS & WEBSTER, P.S. Exhibit 16.1 WILLIAMS & WEBSTER, P.S. Certified Pubic Accountants 601 West Riverside Suite 1940 Spokane, Washington 99201 (509) 838-5111 FAX: (509) 838 5114 October 29, 2002 Securities and Exchange Commission 450 Fifth Street SW Washington, DC 20549 Re: Ancona Mining Corporation Commission File Number 333-94835 Dear Sirs: We are in agreement |
|
| October 23, 2002 |
8-K 1 ancona8k.htm FORM 8-K FOR ANCONA MINING CORPORATION ================================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report October 18, 2002 ANCONA MINING CORPORATION (Exact name of registrant as specified in its charter) NE |
|
| September 26, 2002 |
FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 [ x ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2002 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 333-94835 ANCONA MINING CORPORATION (Exact nam |
|
| May 9, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB 10QSB 1 ancq33102.htm ANCONA MINING CORPORATION FORM 10-QSB ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [ x ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the QUARTERLY PERIOD ENDED MARCH 31, 2002 OR [ ] Transition Report Pursuant to S |
|
| February 6, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB 10QSB 1 anc123102.htm ANCONA MINING CORPORATION FORM 10QSB ============================================================================= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2001 OR [ ] Transition Report Pursuant to Sect |
|
| November 7, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB 10QSB 1 anc9301.htm ANCONA MINING CORPORATION FORM 10-QSB FOR THE PERIOD ENDED SEPTEMBER 30, 2001 ========================================================================= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTMBER 30, 2001 OR [ ] |
|
| September 27, 2001 |
SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 8-A12G 1 anco8a.htm ANCONA MINING CORPORATION FORM 8-A SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 Form 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANCONA MINING CORPORATION (Exact name of registrant as specified in its charter.) Nevada (State of incorporation of organization) 88-0436055 (I.R.S. Employ |
|
| August 29, 2001 |
FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 [ x ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended - June 30, 2001 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 333-94835 ANCONA MINING CORPORATION (Exact nam |
|
| May 15, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB ========================================================================= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10QSB [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2001 OR [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the tra |
